Fixed drug eruption due to foscarnet.

AUTOR(ES)

Connolly, G M

RESUMO

A case of fixed drug eruption (FDE) secondary to foscarnet is reported. This drug has recently become available on a compassionate use basis for treatment of cytomegalovirus (CMV) infection which may cause significant disease in immunosuppressed patients. Foscarnet provides a useful alternative to the only licensed anti-CMV drug currently available, namely ganciclovir (DHPG), as it has a different toxicity profile. In particular, it does not appear to cause bone marrow suppression which is of importance in AIDS patients as many of them are taking concurrent zidovudine.

Documentos Relacionados

• Balanitis due to fixed drug eruption associated with tetracycline therapy.
• Fixed Eruption due to Sulphonamide Hypersensitivity*
• Balanitis due to fixed eruption after Mandrax.
• Vulval ulceration associated with foscarnet.
• Fixed drug eruption to nimesulide: an exuberant presentation confirmed by patch testing